A detailed history of Price T Rowe Associates Inc transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 24,900 shares of PDSB stock, worth $53,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,900
Previous 24,900 -0.0%
Holding current value
$53,535
Previous $73,000 31.51%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.55 - $4.02 $18,770 - $29,591
7,361 Added 41.97%
24,900 $73,000
Q1 2024

May 15, 2024

BUY
$3.85 - $6.59 $6,876 - $11,769
1,786 Added 11.34%
17,539 $70,000
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $4,605 - $7,672
1,166 Added 7.99%
15,753 $79,000
Q2 2023

Aug 14, 2023

BUY
$5.03 - $9.9 $73,372 - $144,411
14,587 New
14,587 $74,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $61.2M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.